Esperion Therapeutics   Report issue

For profit Phase 2 Phase 3
Founded: Ann Arbor MI United States (2008)

Organization Overview

First Clinical Trial
2010
NCT01105598
First Marketed Drug
2020
bempedoic acid
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Esperion Therapeutics | Esperion Therapeutics, Inc. | ESPERION THERAPS INC

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Atherosclerosis (Phase 3)

Cardiovascular Diseases (Phase 3)

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 2 (Phase 2)

Dyslipidemias (Phase 2)

Hypercholesterolemia (Phase 3)

Hyperlipidemias (Phase 3)

Hyperlipoproteinemias (Phase 3)

Hypertension (Phase 2)

Hypertriglyceridemia (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 21
  • # of Trial APIs: 7